Journey with AxxessBio:
Stay informed with our latest news, press releases and shared milestones

AxxessBio announces an exclusive distribution agreement with ADIENNE for TEPADINA® (Thiotepa)

June 2020, AxxessBio announces an exclusive distribution agreement with ADIENNE (Lugano – Switzerland) for TEPADINA® (Thiotepa) for Singapore, Thailand, Malaysia, Vietnam, Philippines and Brunei.

TEPADINA® 15mg and 100mg powder for concentrate for solution for infusion is used in combination with other chemotherapy medicinal products, as conditioning treatment prior to allogeneic or autologous hematopoietic stem cell transplantation in hematological diseases or solid tumors in adults and children. The use of TEPADINA® has impacted significantly the lives of patients by improving their disease free and overall survival after transplant.

ADIENNE is an integrated biopharmaceutical group of companies based in Switzerland, with manufacturing sites for cytotoxic product and monoclonal antibody, with a proprietary portfolio of orphan-designated marketed medicinal products, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

ADIENNE aims to develop a range of product candidates for orphan diseases for which existing treatment options are limited, the patient population is small and the clinical needs for therapies is high. For more information on ADIENNE and its products please visit

Interested in Partnering Up?

At AxxessBio, we are continuously looking for partnerships to bring new innovative therapies for patients all around Asia